BNP Paribas Financial Markets
FTH

BNP Paribas Financial Markets’s Faeth Therapeutics FTH Stock Holding History

BNP Paribas Financial Markets’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$284 Hold
9
– – ﹤0.01% 5601
2025
Q4 		$96 Hold
9
– – ﹤0.01% 5614
2025
Q3 		$85 Hold
9
– – ﹤0.01% 5444
2025
Q2 		$77 Buy
9
+1
+13% +$7 ﹤0.01% 5337
2025
Q1 		$63 Hold
8
– – ﹤0.01% 5282
2024
Q4 		$78 Buy
+8
New +$80 ﹤0.01% 5295
2022
Q4 		– Sell
-30
Closed -$935 – 4551
2022
Q3 		$935 Buy
+30
New +$1.18K ﹤0.01% 4437

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BNP Paribas Financial Markets's FTH Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Faeth Therapeutics (FTH) position steady in Q1 2026 at 9 shares worth $284. The position accounts for ﹤0.01% of the portfolio, ranked #5601.

BNP Paribas Financial Markets first reported a position in FTH in Q3 2022 and has held it in 7 quarters since. The position peaked at $935 in Q3 2022. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • BNP Paribas Financial Markets held 9 shares of Faeth Therapeutics worth $284 as of Q1 2026.
  • BNP Paribas Financial Markets left its Faeth Therapeutics share count unchanged in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5601 holding.
  • BNP Paribas Financial Markets first reported a position in Faeth Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Faeth Therapeutics position peaked at $935 in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.